• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

About FDA

  • Print
  • Share
  • E-mail

Appendix C: Crosswalk between FDA’s Strategic Planning Documents


Previous Strategic Action Plan Framework
Current Strategic Priorities Framework
1.1: Strengthen the scientific foundation of FDA's regulatory mission
Cross-Cutting: Advance Regulatory Science and Innovation; see also various medical product strategies
3.1.1.3: Ensure adequate scientific capacity to support risk-based public health decision making
3.2.3.1: Enhance knowledge of emerging science and technologies
3.4.1: Recruit, develop, retain, and strategically manage a world-class workforce
1.2: Cultivate a culture that promotes transparency, effective teamwork, and mutual respect and ensures integrity and accountability in regulatory decision making
3.4.7: Improve transparency, collaboration, and participation 
1.3: Enhance partnerships and communications
3.2.2.1: Increase the nation's preparedness to address threats as a result of bioterrorism, pandemic and emerging infectious diseases
3.2.2.2: Improve global public health through international collaboration including research and information sharing
3.4.5: Improve the management of FDA by providing ongoing oversight, evaluation, and analysis of policies and programs and by ensuring effective strategic communications
3.4.7: Improve transparency, collaboration, and participation
Cross-Cutting: Advance Medical Countermeasures and Emergency Preparedness
Cross-Cutting: Strengthen the Safety and Integrity of the Global Supply Chain
1.4: Strengthen FDA's base of operations
3.4.1: Recruit, develop, retain, and strategically manage a world-class workforce
3.4.2: Ensure program integrity and responsible stewardship through effective administration of fiduciary responsibilities 
3.4.3: Implement an IT modernization program to support state-of-the-art networked information and shared data resources
3.4.4 : Ensure facilities infrastructure provides dynamic capabilities
3.4.6: Foster a culture of continual business process improvement to improve the overall operation and effectiveness of FDA 
2.1: Strengthen the science that supports product safety
Cross-Cutting: Advance Regulatory Science and Innovation
3.2.1.3 Protect public health by promoting the safe use of marketed drugs
3.2.2.2: Improve global public health through international collaboration, including research and information sharing 
3.2.3.1: Enhance knowledge of emerging science and technologies
2.2: Improve information systems for problem detection and public communication about product safety
3.2.1.3: Protect public health by promoting the safe use of marketed drugs
3.4.3: Implement an IT modernization program to support state-of-the-art networked information and shared data resources
2.3: Provide patients and consumers with better access to clear and timely risk-benefit information for medical products
3.2.1.3: Protect public health by promoting the safe use of marketed drugs
3.2.2.4: Ensure the safety of biological products
3.2.4.1: Fully implement a total product life cycle approach that enables well-supported regulatory decisions at any stage of a device's cycle
3.2.3.3: Ensure the judicious use of medically important antimicrobials
2.4: Provide consumers with clear and timely information to protect them from foodborne illness and promote better nutrition
3.1.2.1: Provide clear and timely information so consumers can choose a healthier diet and reduce the risk of chronic disease and obesity
3.1: Increase the number of safe and effective new medical products available to patients
3.2.1.1: Promote public health by ensuring the availability of safe and effective new drugs
3.2.2.1: Increase the nation's preparedness to address threats as a result of bioterrorism, pandemic and emerging infectious diseases
3.2.2.3: Enhance the ability of advanced science and technology to facilitate development of safe and effective biological products
3.2.3.2: Reduce risk of harm from substandard and illegally marketed animal drugs
3.2.3.4: Increase access to safe and effective animal drugs and reduce risk of harm from unsafe use of marketed animal drugs
3.2.4.1: Fully implement a total product life cycle approach that enables well-supported regulatory decisions at any stage of a device's cycle
3.2.4.2: Proactively facilitate innovation and address unmet public health needs
Cross cutting: Expand Efforts to Meet Needs of Special Populations
3.2: Improve the medical product review process to increase the predictability and transparency of decisions using the best available science
3.2.2.3: Enhance the ability of advanced science and technology to facilitate development of safe and effective biological products
3.3: Increase access to safe and nutritious new food products
3.1.2.1: Provide clear and timely information so consumers can choose a healthier diet and reduce the risk of chronic disease and obesity
3.1.2.2: Encourage product reformulation to increase the availability of nutritious food products
4.1: Prevent safety problems by modernizing science-based standards and tools to ensure high-quality manufacturing, processing, and distribution
3.1.1.1: Establish standards for science-based preventive controls throughout the farm to table continuum
3.1.1.2: Achieve high rates of compliance with preventive control standards, both domestically and internationally
3.2.1.2: Protect public health by ensuring the quality and integrity of marketed drug products
3.2.2.3: Enhance the ability of advanced science and technology to facilitate development of safe and effective biological products
3.2.3.2: Reduce risk of harm from substandard and illegally marketed animal drugs
4.2: Detect safety problems earlier and better target interventions to prevent harm to consumers
3.1.1.1: Establish standards for science-based preventive controls throughout the farm to table continuum
3.1.1.2: Achieve high rates of compliance with preventive control standards, both domestically and internationally
3.2.3.2: Reduce risk of harm from substandard and illegally marketed animal drugs
3.2.3.4: Increase access to safe and effective animal drugs and reduce risk of harm from unsafe use of marketed animal drugs
3.2.4.1: Fully implement a total product life cycle approach that enables well-supported regulatory decisions at any stage of a device's cycle
Cross-Cutting: Strengthen Compliance and Enforcement Activities to Support Public Health
4.3: Respond more quickly and effectively to emerging safety problems, through better information, better coordination, and better communication
3.1.1.2: Achieve high rates of compliance with preventive control standards, both domestically and internationally
3.2.2.1: Increase the nation's preparedness to address threats as a result of bioterrorism, pandemic and emerging infectious diseases
3.2.3.5: Enhance response to food/feed and drug safety events
Cross-Cutting: Advance Medical Countermeasures and Emergency Preparedness
Cross-Cutting: Strengthen the Safety and Integrity of the Global Supply Chain

Back to top